Replidyne raises $40 million

Replidyne (Louisville, Colo.) raised $40 million in a series B round led by TPG Ventures. Other investors in the infectious disease company included Perseus-Soros Biopharmaceutical Fund; HealthCare Ventures; Morgenthaler Ventures; and Sequel Venture Partners. In conjunction with the financing, Geoffrey Duyk, managing director at TPG, and Christopher Earl, managing director at Perseus-Soros, will join Replidyne's board. The company said it has raised a total of $53 million since February 2002. ...